Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Moodys

Last Updated: March 24, 2023

Peginesatide acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for peginesatide acetate and what is the scope of freedom to operate?

Peginesatide acetate is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Peginesatide acetate has one hundred and fourteen patent family members in thirty-four countries.

Summary for peginesatide acetate
International Patents:114
US Patents:6
Tradenames:2
Applicants:1
NDAs:1
DailyMed Link:peginesatide acetate at DailyMed

US Patents and Regulatory Information for peginesatide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for peginesatide acetate

Country Patent Number Title Estimated Expiration
African Intellectual Property Organization (OAPI) 13164 Novel peptides that bind to the erythropoietin receptor. See Plans and Pricing
South Africa 200509971 Peptides that bind to the erythropoietin receptor See Plans and Pricing
Mexico 2007015303 FORMULACIONES Y USOS DEL PEPTIDO RECEPTOR DE ERITROPOYETINA. (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES.) See Plans and Pricing
Eurasian Patent Organization 200501798 НОВЫЕ ПЕПТИДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С РЕЦЕПТОРОМ К ЭРИТРОПОЭТИНУ See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Mallinckrodt
AstraZeneca
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.